ASP Isotopes Shares Rise After Preliminary Nuclear-Fuel Supply Agreement

Dow Jones05-11
 

By Adriano Marchese

 

ASP Isotopes shares rose after it said it signed a preliminary agreement with a European nuclear-technology company to assess the viability supplying of high assay low enriched uranium, or HALEU.

Shares traded 8% higher at $5.81.

ASP Isotopes said Monday its subsidiary Quantum Leap Energy signed a nonbinding memorandum of understanding with an advanced-nuclear-reactor company in Europe to explore a long-term partnership to supply HALEU, the specialized nuclear fuel needed for next-generation reactors.

Ryno Pretorius, the chief executive of Quantum Leap Energy, said the agreement is an early step toward the company's goal of building enrichment capabilities that serve both U.S. and global markets.

The potential arrangement would see the European reactor developer provide uranium to Quantum Leap Energy's planned U.S. facilities. Quantum Leap Energy would then process and enrich that material into HALEU for the partner. The assessment will look at technical needs, costs, and how production could scale over time.

The term of the memorandum extends through the end of 2030, and includes nonbinding estimates of quantities of the material, with potential deliveries beginning in 2028 and quantities scaling up through 2036.

 

Write to Adriano Marchese at adriano.marchese@wsj.com

 

(END) Dow Jones Newswires

May 11, 2026 11:01 ET (15:01 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment